Lisata Therapeutics to be Acquired by Kuva Labs for $5 per Share

Lisata Therapeutics' shares surged 20% after the company agreed to be acquired by privately-held Kuva Labs for $5 per share in cash, plus a potential additional $1 per share if a regulatory milestone is achieved. The deal is expected to close in Q2 2026, following a tender offer and second-step merger. Lisata's board of directors approved the agreement after a comprehensive strategic review, recommending that shareholders tender their shares.